Search

Your search keyword '"Bruera, Gemma"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Bruera, Gemma" Remove constraint Author: "Bruera, Gemma"
142 results on '"Bruera, Gemma"'

Search Results

1. Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

2. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study

8. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

9. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A

12. 846421_supplementary_mater – Supplemental material for Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

13. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

14. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study

15. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study

16. Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study

18. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

19. 'Poker' association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

20. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

21. Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

22. Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer

23. KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease

24. Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

25. Abstract A052: Predictive wild-typeRAS/BRAFand pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy

28. Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line FIr-B/FOx adding bevacizumab to triplet chemotherapy

29. Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.

30. Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.

34. Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study

36. Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab.

41. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines

43. KRAS Genotype and the Prevalent C.35 G > A Mutation Affect Significantly Worse Prognosis of Metastatic Colorectal Cancer (MCRC) Patients Fitting for Intensive Fir-B/Fox Triplet Chemotherapy Plus Bevacizumab

45. Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) and post-progression.

46. Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

48. P-0266 Worse Prognosis of Kras C.35 G>A Mutant Mcrc Patients Treated with Intensive Triplet Chemotherapy Plus Bevacizumab (FIR-B/FOX)

49. Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to KRAS genotype and disease extension.

50. Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).

Catalog

Books, media, physical & digital resources